UY37936A - AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 - Google Patents
AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1Info
- Publication number
- UY37936A UY37936A UY0001037936A UY37936A UY37936A UY 37936 A UY37936 A UY 37936A UY 0001037936 A UY0001037936 A UY 0001037936A UY 37936 A UY37936 A UY 37936A UY 37936 A UY37936 A UY 37936A
- Authority
- UY
- Uruguay
- Prior art keywords
- agents
- expression
- inhibit
- compositions
- asgr1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente memoria da a conocer composiciones y métodos para la inhibición de la expresión génica del receptor de asialoglicoproteína 1 (ASGR1). Se dan a conocer agentes de interferencia de ARN (iARN), por ejemplo, agentes iARN de doble hebra, y conjugados agente iARN-ligando dirigido a la diana para inhibir la expresión de un gen ASGR1. También se dan a conocer composiciones farmacéuticas que comprenden uno o más agentes iARN ASGR1, opcionalmente con uno o más agentes terapéuticos adicionales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762573206P | 2017-10-17 | 2017-10-17 | |
US201762608606P | 2017-12-21 | 2017-12-21 | |
US201862635277P | 2018-02-26 | 2018-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY37936A true UY37936A (es) | 2019-05-31 |
Family
ID=66173364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001037936A UY37936A (es) | 2017-10-17 | 2018-10-17 | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11492624B2 (es) |
EP (1) | EP3697909A4 (es) |
JP (2) | JP7473472B2 (es) |
CN (1) | CN111212909A (es) |
AU (1) | AU2018352379A1 (es) |
CA (1) | CA3079413A1 (es) |
TW (1) | TW201918555A (es) |
UY (1) | UY37936A (es) |
WO (1) | WO2019079294A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116832169A (zh) * | 2016-09-02 | 2023-10-03 | 箭头药业股份有限公司 | 靶向配体 |
CN116617390A (zh) * | 2022-02-11 | 2023-08-22 | 武汉大学 | Asgr1抑制剂在促进胆固醇外排和治疗非酒精性脂肪性肝病中的应用 |
CN117645995A (zh) * | 2022-09-02 | 2024-03-05 | 北京福元医药股份有限公司 | 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
AU767195B2 (en) | 1999-03-10 | 2003-11-06 | Phogen Limited | Delivery of substances to cells |
US8137695B2 (en) | 2006-08-18 | 2012-03-20 | Arrowhead Madison Inc. | Polyconjugates for in vivo delivery of polynucleotides |
CN1300312C (zh) * | 2004-08-23 | 2007-02-14 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途 |
EP2087110A2 (en) * | 2006-10-11 | 2009-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Influenza targets |
EP2295543A1 (en) * | 2009-09-11 | 2011-03-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the preparation of an influenza virus |
EP3023495B1 (en) | 2010-02-24 | 2019-05-08 | Arrowhead Pharmaceuticals, Inc. | Compositions for targeted delivery of sirna |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
AU2012300476B2 (en) | 2011-08-26 | 2016-03-24 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
CN103764153A (zh) | 2012-04-18 | 2014-04-30 | 箭头研究公司 | 用于体内核酸递送的聚(丙烯酸酯)聚合物 |
JP2018535655A (ja) * | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | Asgr阻害剤 |
JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
CN109069529B (zh) | 2016-03-07 | 2021-08-20 | 箭头药业股份有限公司 | 用于治疗性化合物的靶向配体 |
UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
CN116832169A (zh) * | 2016-09-02 | 2023-10-03 | 箭头药业股份有限公司 | 靶向配体 |
-
2018
- 2018-10-16 JP JP2020521451A patent/JP7473472B2/ja active Active
- 2018-10-16 US US16/756,440 patent/US11492624B2/en active Active
- 2018-10-16 WO PCT/US2018/056077 patent/WO2019079294A1/en unknown
- 2018-10-16 CN CN201880066319.0A patent/CN111212909A/zh active Pending
- 2018-10-16 EP EP18868368.4A patent/EP3697909A4/en active Pending
- 2018-10-16 CA CA3079413A patent/CA3079413A1/en active Pending
- 2018-10-16 AU AU2018352379A patent/AU2018352379A1/en active Pending
- 2018-10-17 UY UY0001037936A patent/UY37936A/es not_active Application Discontinuation
- 2018-10-17 TW TW107136576A patent/TW201918555A/zh unknown
-
2024
- 2024-04-11 JP JP2024064086A patent/JP2024086876A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3697909A1 (en) | 2020-08-26 |
EP3697909A4 (en) | 2021-10-13 |
WO2019079294A1 (en) | 2019-04-25 |
CN111212909A (zh) | 2020-05-29 |
JP7473472B2 (ja) | 2024-04-23 |
TW201918555A (zh) | 2019-05-16 |
CA3079413A1 (en) | 2019-04-25 |
JP2024086876A (ja) | 2024-06-28 |
JP2020537653A (ja) | 2020-12-24 |
AU2018352379A1 (en) | 2020-06-04 |
US11492624B2 (en) | 2022-11-08 |
US20200283777A1 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502333A1 (en) | Targeted compositions | |
BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
CR20190294A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
PH12020550833A1 (en) | Rnai constructs for inhibiting pnpla3 expression | |
BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
JO3558B1 (ar) | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) | |
MX2023012080A (es) | Composiciones de acido ribonucleico interferente (arni) de transtiretina (ttr) y sus usos en el tratamiento o prevencion de enfermedades asociadas con transtiretina (ttr). | |
BR112018008746A2 (pt) | composições e métodos para a inibição de atividade de arginase | |
CO2020015314A2 (es) | Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso | |
BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
BR112017020895A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
NZ724277A (en) | Compositions and methods for modulating pkk expression | |
PE20142362A1 (es) | Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr) | |
PE20210921A1 (es) | Agentes arni como inhibidores de la transcripcion de la serpina 1 y composiciones que los comprenden | |
UY37936A (es) | AGENTES iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DEL RECEPTOR DE ASIALOGLICOPROTEÍNA 1 | |
CR20210371A (es) | Constructos de arni para inhibir la expresión de pnpla3 | |
GEP20217318B (en) | Pyrazole magl inhibitors | |
MX2019002271A (es) | Construcciones de arni para inhibir expresion de asgr1 y metodos para su uso. | |
EP4219715A3 (en) | Stabilized cebpa sarna compositions and methods of use | |
UY37800A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
MX2021014465A (es) | Construcciones de arni para inhibir la expresion de scap y metodos de uso de las mismas. | |
PH12020550244A1 (en) | Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages | |
WO2020104649A3 (en) | Novel rna compositions and methods for inhibiting angptl8 | |
WO2016103042A8 (en) | Compositions and methods for inhibiting expression of adamts-5 and adam17 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201203 |